Retatrutide and GLP-1 Agonist Developments in Obesity Treatment | Retatrutide News

Eli Lilly is advancing its metabolic pipeline with Retatrutide, a promising GLP-1 agonist for obesity treatment. AI is playing a role in the development...
Market News · October 13, 2026